Hypertension Journal

Register      Login

VOLUME 3 , ISSUE 2 ( April-June, 2017 ) > List of Articles


Endothelial Dysfunction and Essential Hypertension

Suegene K Lee, Jay Khambhati, Pratik B Sandesara, Arshed A Quyyumi, Bryan Kindya, Devinder Dhindsa

Citation Information : Lee SK, Khambhati J, Sandesara PB, Quyyumi AA, Kindya B, Dhindsa D. Endothelial Dysfunction and Essential Hypertension. Hypertens J 2017; 3 (2):81-88.

DOI: 10.5005/jp-journals-10043-0076

Published Online: 01-09-2016

Copyright Statement:  Copyright © 2017; The Author(s).


How to cite this article

Khambhati J, Lee SK, Kindya B, Dhindsa D, Sandesara PB, Quyyumi AA. Endothelial Dysfunction and Essential Hypertension. Hypertens J 2017;3(2):81-88.

PDF Share
  1. Clinical significance of endothelial dysfunction in essential hypertension. Curr Hypertens Rep 2015 Nov;17(11):85.
  2. Endothelial dysfunction and hypertension. Adv Exp Med Biol 2017;956:511-540.
  3. Regulatory functions of the vascular endothelium. N Engl J Med 1990 Jul;323(1):27-36.
  4. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990 Jul;323(1):22-27.
  5. Nitric oxide activity in the atherosclerotic human coronary circulation. J Am Coll Cardiol 1997 Feb;29(2):308-317.
  6. Endothelial dysfunction and hypertension: cause or effect? Hypertension 2010 May;55(5):1092-1094.
  7. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 2006;46:235-276.
  8. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003 Nov;9(11):1370-1376.
  9. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 1995 Apr;95(4):1747-1755.
  10. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995 Aug;92(3):320-326.
  11. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990 Jun;81(6):1762-1767.
  12. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995 Mar;91(6):1732-1738.
  13. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994 Jul;90(1):35-41.
  14. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol 1995 Feb;75(4):264-268.
  15. Evidence that endothelial dysfunction in patients with hypercholesterolemia is not due to increased extracellular nitric oxide breakdown by superoxide anions. Am J Cardiol 1995 Dec;76(16):1157-1161.
  16. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation 1998 Mar;97(9):851-856.
  17. Decreased vasodilator response to isoproterenol during nitric oxide inhibition in humans. Hypertension 1997 Oct;30(4):918-921.
  18. Role of nitric oxide in the vasodilator response to mental stress in normal subjects. Am J Cardiol 1997 Oct;80(8):1070-1074.
  19. Increased activity of endogenous endothelin in hypercholesterolemic patients. Circulation 1997;96(8): 1395-1395.
  20. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997 Jul;30(1 Pt 1):57-63.
  21. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995 Nov;26(5):1235-1241.
  22. Prognostic value of flow-mediated vasodilation in brachial artery and fingertip artery for cardiovascular events: a systematic review and meta-analysis. J Am Heart Assoc 2015 Nov;4(11):e002270.
  23. Non-invasive endothelial function testing and the risk of adverse outcomes: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging 2014 Jul;15(7):736-746.
  24. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009 Aug;120(6):502-509.
  25. Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women. J Am Coll Cardiol 2008 Mar;51(10):997-1002.
  26. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007 May;115(18):2390-2397.
  27. Predictive value of endothelial function by noninvasive peripheral arterial tonometry for coronary artery disease. Coron Artery Dis 2015 May;26(3):231-238.
  28. Transient hypertension directly impairs endothelium-dependent vasodilation of the human microvasculature. Hypertension 2000 Dec;36(6):941-944.
  29. Elevated blood pressure in adolescent boys predicts endothelial dysfunction: the cardiovascular risk in young Finns study. Hypertension 2006 Sep;48(3):424-430.
  30. Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension 1990 Aug;16(2):170-179.
  31. Nitric oxide in hypertension. J Clin Hypertens (Greenwich) 2006 Dec;8(12 Suppl 4):17-29.
  32. Endothelial dysfunction and the risk of hypertension: the multi-ethnic study of atherosclerosis. Hypertension 2010 May;55(5):1210-1216.
  33. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med 1994 Apr;330(15):1036-1040.
  34. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993 May;87(5):1468-1474.
  35. ; Murrow, J.; Kavtaradze, N.; Sheikh, A.; Jorgensen, J.; Pohel, K.; Manatunga, A.; Quyyumi, A. The contribution of endothelial-derived hyperpolarising factor and nitric oxide to basal and stimulatory vasodilator tone in metabolic syndrome. Paper presented at: Annual Scientific Conference of the British-Cardiovascular-Society; Jun 02-04, 2008. Manchester, England.
  36. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 2000 Jun;35(6):1237-1241.
  37. Improved endothelium-dependent vasodilation after block-ade of endothelin receptors in patients with essential hypertension. Circulation 2002 Jan;105(4):452-456.
  38. Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients. Circulation 2004 Jun;109(25):3191-3195.
  39. Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertension. J Hypertens 2009 Dec;27(12):2310-2320.
  40. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension 1999 Apr;33(4):937-942.
  41. The T-786-C mutation in endothelial nitric oxide synthase is associated with hypertension. Hypertension 2002 Apr;39(4):919-922.
  42. Defective L-arginine-nitric oxide pathway in off-spring of essential hypertensive patients. Circulation 1996 Sep;94(6):1298-1303.
  43. Endothelial dysfunction and the risk of hypertension: the multi-ethnic study of atherosclerosis. Hypertension 2010 May;55(5):1210-1216.
  44. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the clinical practice discussion group. Circulation 2004 Dec;110(25):e550-e553.
  45. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005 Aug;46(3):518-523.
  46. Association between asymmetric dimethylarginine and indices of vascular function in patients with essential hypertension. Blood Press 2011 Apr;20(2):111-116.
  47. Asymmetric dimethylarginine (ADMA) has a role in regulating systemic vascular tone in young healthy subjects: the cardiovascular risk in young Finns study. Am J Hypertens 2008 Aug;21(8):873-878.
  48. The association between biomarker profiles, etiology of chronic kidney disease, and mortality. Am J Nephrol 2017 Feb;45(3):226-234.
  49. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc 2015 May;4(6):e001833.
  50. Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: a meta-analysis based on 4713 participants. Eur J Prev Cardiol 2016 Mar;23(5):502-510.
  51. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003 Feb;91(3A):7A-11A.
  52. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 2008 Oct;295(4):C849-C868.
  53. Thiol/disulfide redox states in signaling and sensing. Crit Rev Biochem Mol Biol 2013 Mar-Apr;48(2):173-181.
  54. Measuring the poise of thiol/disulfide couples in vivo. Free Radic Biol Med 2009 Nov;47(10):1329-1338.
  55. The relationship between plasma levels of oxidized and reduced thiols and early atherosclerosis in healthy adults. J Am Coll Cardiol 2006 Mar;47(5):1005-1011.
  56. Oxidative stress is associated with impaired arterial elasticity. Atherosclerosis 2011 Sep;218(1):90-95.
  57. Intracellular proatherogenic events and cell adhesion modulated by extracellular thiol/disulfide redox state. Circulation 2005 Jun;111(22):2973-2980.
  58. Glutathione and thioredoxin redox during differentiation in human colon epithelial (Caco-2) cells. Am J Physiol Gas-trointest Liver Physiol 2002 Dec;283(6):G1352-G1359.
  59. The plasma redox state and ageing. Ageing Res Rev 2002 Apr;1(2):257-278.
  60. Glutathione in human plasma: decline in association with aging, age-related macular degeneration, and diabetes. Free Radic Biol Med 1998 Mar;24(5):699-704.
  61. Plasma glutathione redox state: a novel marker of oxidative stress, correlates with early atherosclerosis in humans. J Am Coll Cardiol 2003;41(Suppl A):293A-294A.
  62. Oxidative stress is associated with increased pulmonary artery systolic pressure in humans. Hypertension 2014 Jun;63(6):1270-1275.
  63. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003 Feb;348(7):593-600.
  64. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997 Feb;275(5302):964-967.
  65. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000 Jan;105(1):71-77.
  66. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998 Jul;105(1A):32S-39S.
  67. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004 Aug;95(4):343-353.
  68. Endothelial progenitor cells functional characterization. Trends Cardiovasc Med 2004 Nov;14(8):318-322.
  69. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 1998 Nov;2(5):549-558.
  70. Stem cell therapy and gene transfer for regeneration. Gene Ther 2000 Mar;7(6):451-457.
  71. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest 2000 Jun;105(11):1527-1536.
  72. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003 Nov;108(20):2511-2516.
  73. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999 Apr;5(4):434-438.
  74. Mechanisms of angiogenesis. Nature 1997 Apr;386(6626):671-674.
  75. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003 Jul;23(7):1143-1151.
  76. Stimulation of endothelial progenitor cells with granulocyte-macrophage colony stimulating factor improves endothelial dysfunction in patients with peripheral arterial disease. J Am Coll Cardiol 2006 Feb;47(4):A381-A384.
  77. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 2000 Oct;87(9):728-730.
  78. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001 Jun;107(11):1395-1402.
  79. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001 Apr;7(4):430-436.
  80. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp Hematol 2002 Aug;30(8):967-972.
  81. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood 2000 Feb;95(3):952-958.
  82. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ Res 2003 Nov;93(10):980-989.
  83. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 2003 Nov;108(21):2710-2715.
  84. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 2002 Oct;22(10):1567-1572.
  85. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003 Jul;108(4):457-463.
  86. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 2000 May;355(9216):1688-1691.
  87. Endothelial progenitor cells: current development of their paracrine factors in cardiovascular therapy. J Cardiovasc Pharmacol 2012 Apr;59(4):387-396.
  88. Stem and progenitor cells for neurological repair: minor issues, major hurdles, and exciting opportunities for paracrine-based therapeutics. J Cell Biochem 2011 Feb;112(2):374-380.
  89. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol 2005 May;45(9):1441-1448.
  90. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2003 Dec;42(12):2073-2080.
  91. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001 Jun;103(24):2885-2890.
  92. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 2003 Nov;108(18):2212-2218.
  93. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002 Nov;106(22):2781-2786.
  94. Endothelial progenitor cells during cerebrovascular disease. Stroke 2005 Jan;36(1):151-153.
  95. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005 Jun;111(22):2981-2987.
  96. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005 Sep;353(10):999-1007.
  97. Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis 2009 Nov;207(1):213-219.
  98. The nature and significance of platelet products in human plasma. Br J Haematol 1967 May;13(3):269-288.
  99. Association of circulating endothelial microparticles with cardiometabolic risk factors in the Framingham Heart Study. Eur Heart J 2014 Nov;35(42):2972-2979.
  100. Role of microparticles in endothelial dysfunction and arterial hypertension. World J Cardiol 2014 Nov;6(11):1135-1139.
  101. Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/Rho kinase pathways targeted to lipid rafts. Arterioscler Thromb Vasc Biol 2011 Aug;31(8):1898-1907.
  102. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001 Nov;104(22):2649-2652.
  103. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003 Feb;41(2):211-217.
  104. Berberine-induced decline in circulating CD31+/CD42-microparticles is associated with improvement of endothelial function in humans. Eur J Pharmacol 2009 Jul;614(1-3): 77-83.
  105. The assessment of endothelial function: from research into clinical practice. Circulation 2012 Aug;126(6):753-767.
  106. Effects of an angiotensin II receptor blocker on the impaired function of endothelial progenitor cells in patients with essential hypertension. Am J Hypertens 2014 May;27(5):695-701.
  107. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. Int J Cardiol 2012 Mar;155(2):279-284.
  108. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis 2011 May;216(1):7-16.
  109. The effects of amlodipine and S(-)-amlodipine on vascular endothelial function in patients with hypertension. Am J Hypertens 2014 Jan;27(1):27-31.
  110. Tetrahydro-biopterin: a novel antihypertensive therapy. J Hum Hypertens 2008 Jun;22(6):401-407.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.